<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363738</url>
  </required_header>
  <id_info>
    <org_study_id>Infliximab-BD</org_study_id>
    <nct_id>NCT02363738</nct_id>
  </id_info>
  <brief_title>12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression</brief_title>
  <official_title>A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Investigation Centre for Innovative Technology Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies show the presence of immuno-inflammatory disturbances in individuals with Bipolar&#xD;
      Disorders (BD). Increased levels of circulating proteins known as cytokines that promote&#xD;
      inflammation have been consistently reported in individuals with bipolar disorders. A&#xD;
      particular cytokine referred to as Tumor Necrosis Factor (TNF)-alpha is among those cytokines&#xD;
      that have been consistently identified across depressive, manic, and euthymic periods.&#xD;
      Disturbances in inflammation however, are not seen in all individual with bipolar disorder.&#xD;
      Those individuals with signs of inflammation also often present with higher prevalence of&#xD;
      medical disorders that are also associated with inflammation. Those individuals with&#xD;
      significant signs of inflammation may respond to anti-inflammatory treatments. In this study,&#xD;
      individuals with bipolar depression who exhibit signs of high inflammation will be enrolled&#xD;
      and treated with either an anti-inflammatory biologic known as infliximab or placebo&#xD;
      (saline).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale scores are provided, with the range of possible values on the scale from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) scores, where the range of possible values on the scale is from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Brain N-acetylaspartate Levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in prefrontal metabolites concentration of N-acetylaspartate, using proton-magnetic resonance spectroscopy (1H-MRS), adjusted for age, sex, baseline values and % gray matter in the spectroscopic region of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Anhedonia</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in the Snaith-Hamilton Pleasure Scale (SHAPS) total score. Total score range of 14 to 56, with greater scores indicative of greater hedonic capacity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
    <arm_group_label>Saline (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fifth edition of Diagnostic and Statistical Manual for Mental Disorders (DSM-5)&#xD;
             criteria for major depressive episode as part of bipolar I/II disorder and are able to&#xD;
             provide written informed consent&#xD;
&#xD;
          -  HAMD-17 score &gt;= 20&#xD;
&#xD;
          -  Young Mania Rating Scale score &lt; 12&#xD;
&#xD;
          -  Previous failed trial (i.e., inefficacy) of quetiapine and one other Canadian Network&#xD;
             for Mood and Anxiety Treatments (CANMAT) BD guideline/FDA approved first line&#xD;
             treatment for the depressive phase of BD during the index episode and/or during a&#xD;
             prior episode&#xD;
&#xD;
          -  Currently prescribed conventional mood stabilizer or atypical antipsychotic agent&#xD;
&#xD;
          -  Received conventional treatment for bipolar depression for a minimum of 4 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Females of childbearing potential must test negative for pregnancy and must be using&#xD;
             adequate birth control measures throughout the study and must continue such&#xD;
             precautions for 6 months after receiving the last study drug administration.&#xD;
&#xD;
        Participants will also need to meet one of the following inflammatory indicators:&#xD;
&#xD;
          1. Central Obesity (ethnicity-specific waist circumference - see table below for specific&#xD;
             values) OR BMI ≥30 kg/m2.&#xD;
&#xD;
             AND&#xD;
&#xD;
               -  Raised triglycerides: ≥1.7 mmol/L (150 mg/dL) or specific treatment for this&#xD;
                  lipid abnormality OR&#xD;
&#xD;
               -  Reduced HDL-cholesterol: &lt;1.03 mmol/L (40 mg/dL) in males; &lt;1.29 mmol/L (50&#xD;
                  mg/dL) in females or specific treatment for this lipid abnormality OR&#xD;
&#xD;
               -  Raised Blood Pressure: Raised blood pressure Systolic: ≥130 mm Hg or diastolic:&#xD;
                  ≥85 mm Hg or treatment of previously diagnosed hypertension.&#xD;
&#xD;
          2. Diabetes: 8-hour fasting plasma glucose ≥ 7.0 mmol/L or Hb-A1C test ≥ 6.5% (as per the&#xD;
             2013 CDA diagnostic criteria) or previously diagnosed type 1 or 2 diabetes (current&#xD;
             prescription medication for diabetes acceptable of diagnosis). Participants with child&#xD;
             onset of diabetes will be excluded.&#xD;
&#xD;
          3. Inflammatory bowel disorder (Ulcerative Colitis, Crohn's disease).&#xD;
&#xD;
          4. Rheumatological disorders (rheumatoid arthiristis); Psoriasis.&#xD;
&#xD;
          5. Smoking cigarettes (daily - minimum of ½ pack).&#xD;
&#xD;
          6. High sensitivity C-reactive protein level of ≥5 mg/L via blood test at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another concurrent psychiatric disorder that requires primary clinical attention&#xD;
&#xD;
          -  History of schizophrenia&#xD;
&#xD;
          -  Active psychotic symptoms&#xD;
&#xD;
          -  Substance abuse and/or dependence within past 6 months&#xD;
&#xD;
          -  Electroconvulsive therapy in the past 6 months&#xD;
&#xD;
          -  Actively suicidal or evaluated as being a suicide risk [HAMD-17 suicide item &gt;= 3 or&#xD;
             Montogomery Asberg Depression Rating Scale (MADRS) suicide item &gt;= 4, or according to&#xD;
             clinical judgement using the C-SSRS]&#xD;
&#xD;
          -  Clinically significant unstable medical illness&#xD;
&#xD;
          -  Severe infections such as sepsis, abscess, tuberculosis and opportunistic infections&#xD;
&#xD;
          -  Viral hepatitis B&#xD;
&#xD;
          -  History of Hepatitis C ( documented or suspected)&#xD;
&#xD;
          -  Any autoimmune disorder&#xD;
&#xD;
          -  History of tuberculosis or a high risk of tuberculosis exposure&#xD;
&#xD;
          -  Human Immunodeficiency Virus confirmed by laboratory testing&#xD;
&#xD;
          -  Active fungal infection&#xD;
&#xD;
          -  History of recurrent viral or bacterial infections&#xD;
&#xD;
          -  Received within 3 months prior to screening or are expected to receive any live viral&#xD;
             vaccine or live bacterial vaccinations during the trial or up to 3 months after the&#xD;
             last administration of study agent&#xD;
&#xD;
          -  C. difficile infection within the past 4 months&#xD;
&#xD;
          -  History of lymphoproliferative disease&#xD;
&#xD;
          -  History of cancer, excluding basal cell or squamous cell carcinoma of the skin (fully&#xD;
             excised with no recurrence)&#xD;
&#xD;
          -  Unstable cardiovascular, endocrinological, hematological, hepatic, renal or&#xD;
             neurological disease determined by physical examination and laboratory testing&#xD;
&#xD;
          -  Concomitant diagnosis or any history of congestive heart failure&#xD;
&#xD;
          -  Concomitant treatment with non-steroidal and steroidal anti-inflammatory medications&#xD;
             or other biologics&#xD;
&#xD;
          -  Current or past exposure to anti-TNF biologics&#xD;
&#xD;
          -  Previous immediate hypersensitivity response, including anaphylaxis to an&#xD;
             immunoglobulin product (plasma-derived or recombinant, e.g. monoclonal antibody)&#xD;
&#xD;
          -  Known allergies, hypersensitivity or intolerance to infliximab or its excipients&#xD;
&#xD;
          -  Known allergy to murine proteins or other chimeric proteins&#xD;
&#xD;
          -  Currently on or have used any investigational drug within 30 days prior to screening,&#xD;
             or within 5 half-lives of the investigational agent&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger S McIntyre, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto; University Health Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>June 14, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Bipolar Depression</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Bipolar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02363738/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02363738/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infliximab</title>
          <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
        <group group_id="P2">
          <title>Saline (Placebo)</title>
          <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant was excluded from the Infliximab arm and 1 participant was excluded from placebo arm of the study because they did not complete at least 1 efficacy assessment after baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>Infliximab</title>
          <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
        <group group_id="B2">
          <title>Saline (Placebo)</title>
          <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="11.7"/>
                    <measurement group_id="B2" value="46.8" spread="10.2"/>
                    <measurement group_id="B3" value="45.71" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="10"/>
                    <measurement group_id="B2" value="34.6" spread="8"/>
                    <measurement group_id="B3" value="34.5" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lifetime psychiatric hospitalizations</title>
          <units>Hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="1.9"/>
                    <measurement group_id="B2" value="1.6" spread="2.0"/>
                    <measurement group_id="B3" value="1.65" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline MADRS total score</title>
          <description>The baseline Montgomery-Asberg Depression Rating Scale (MADRS) score is used to assess the baseline depressive symptoms. The range of possible values on the scale is 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="7.2"/>
                    <measurement group_id="B2" value="29.5" spread="7"/>
                    <measurement group_id="B3" value="30" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline YMRS total score</title>
          <description>The Young Mania Rating Scale (YMRS) total score ranges from 0 to 60, where higher scores indicate more severe mania.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="3.0"/>
                    <measurement group_id="B2" value="4.4" spread="4.2"/>
                    <measurement group_id="B3" value="3.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bipolar I disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bipolar II disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College or university</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graduate school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP level, age-adjusted</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="3.3"/>
                    <measurement group_id="B2" value="7.3" spread="8.1"/>
                    <measurement group_id="B3" value="7.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory criteria met</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>CRP level greater than or equal to 5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity combined with hypertension or dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes type 1 or 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory bowel disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rheumatologic disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily cigarette smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lithium carbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valproate sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quetiapine fumarate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Olanzapine and fluoxetine hydrochloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lurasidone hydrochloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lamotrigine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antidepressant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</title>
        <description>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale scores are provided, with the range of possible values on the scale from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>The modified intent-to-treat analysis included all participants who had received at least 1 infusion of study medication and completed at least 1 after-baseline efficacy assessment. One participant from the Infliximab arm and one participant from the placebo arm were excluded fromt he analyses because they did not complete at least one efficacy assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
          <group group_id="O2">
            <title>Saline (Placebo)</title>
            <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</title>
          <description>Baseline and Week 12 Montgomery-Asberg Depression Rating Scale scores are provided, with the range of possible values on the scale from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
          <population>The modified intent-to-treat analysis included all participants who had received at least 1 infusion of study medication and completed at least 1 after-baseline efficacy assessment. One participant from the Infliximab arm and one participant from the placebo arm were excluded fromt he analyses because they did not complete at least one efficacy assessment after baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.61" spread="1.36"/>
                    <measurement group_id="O2" value="27.79" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week. 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.64" spread="2.40"/>
                    <measurement group_id="O2" value="16.06" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</title>
        <description>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) scores, where the range of possible values on the scale is from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
        <time_frame>Up to 6 weeks</time_frame>
        <population>The modified intent-to-treat analysis included all participants who had received at least 1 infusion of study medication and completed at least 1 after-baseline efficacy assessment. One participant from the Infliximab arm and one participant from the placebo arm were excluded fromt he analyses because they did not complete at least one efficacy assessment after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
          <group group_id="O2">
            <title>Saline (Placebo)</title>
            <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) Scores</title>
          <description>Baseline and Week 6 Montgomery-Asberg Depression Rating Scale (MADRS) scores, where the range of possible values on the scale is from 0 to 60. The higher the score, the worse the overall depressive symptoms.</description>
          <population>The modified intent-to-treat analysis included all participants who had received at least 1 infusion of study medication and completed at least 1 after-baseline efficacy assessment. One participant from the Infliximab arm and one participant from the placebo arm were excluded fromt he analyses because they did not complete at least one efficacy assessment after baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.61" spread="1.36"/>
                    <measurement group_id="O2" value="27.79" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.44" spread="2.27"/>
                    <measurement group_id="O2" value="20.94" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Brain N-acetylaspartate Levels</title>
        <description>Changes in prefrontal metabolites concentration of N-acetylaspartate, using proton-magnetic resonance spectroscopy (1H-MRS), adjusted for age, sex, baseline values and % gray matter in the spectroscopic region of interest.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The number of total participants analyzed is lower than those previously reported in the primary outcome measure as only a subgroup of participants underwent this additional and optional MRS testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
          <group group_id="O2">
            <title>Saline (Placebo)</title>
            <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain N-acetylaspartate Levels</title>
          <description>Changes in prefrontal metabolites concentration of N-acetylaspartate, using proton-magnetic resonance spectroscopy (1H-MRS), adjusted for age, sex, baseline values and % gray matter in the spectroscopic region of interest.</description>
          <population>The number of total participants analyzed is lower than those previously reported in the primary outcome measure as only a subgroup of participants underwent this additional and optional MRS testing.</population>
          <units>mmol/kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="0.09"/>
                    <measurement group_id="O2" value="5.65" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="0.21"/>
                    <measurement group_id="O2" value="5.81" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Anhedonia</title>
        <description>Change in the Snaith-Hamilton Pleasure Scale (SHAPS) total score. Total score range of 14 to 56, with greater scores indicative of greater hedonic capacity.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Three participants in the Infliximab group did not complete at least one post-baseline efficacy assessment. Three participants did not complete at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
          <group group_id="O2">
            <title>Saline (Placebo)</title>
            <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Anhedonia</title>
          <description>Change in the Snaith-Hamilton Pleasure Scale (SHAPS) total score. Total score range of 14 to 56, with greater scores indicative of greater hedonic capacity.</description>
          <population>Three participants in the Infliximab group did not complete at least one post-baseline efficacy assessment. Three participants did not complete at least one post-baseline efficacy assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.04" spread="1.73"/>
                    <measurement group_id="O2" value="34.8" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.17" spread="1.5"/>
                    <measurement group_id="O2" value="40.79" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from screening (prior to baseline) through the completion of the study at week 12 (minimum of 3 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infliximab</title>
          <description>Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation&#xD;
Infliximab: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
        <group group_id="E2">
          <title>Saline (Placebo)</title>
          <description>Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.&#xD;
Saline: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <description>A participant who received infliximab at the Stanford site died due to anoxic brain injury approximately 4 weeks after the third infusion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.44</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function enzymes</sub_title>
                <description>Replicated abnormalities in laboratory assessments of liver function (ie, alanine aminotransferase and aspartate aminotransferase levels) without associated symptoms after 2 infusions of infliximab, patient dismissed from study before third infusion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Reactive arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger McIntyre</name_or_title>
      <organization>University Health Network</organization>
      <phone>416-603-5279</phone>
      <email>roger.mcintyre@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

